AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11170991
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of RTS,S/SBAS2
Trial: 11170991
Drug: 3 standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 standard doses of RTS,S/SBAS2
Trial: 11170991
Drug: 3 one-half
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 one-half doses of RTS,S/SBAS2
Trial: 11170991
Drug: 3 one-fifth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 one-fifth doses of RTS,S/SBAS2
Trial: 9779247
Drug: Topical and
RxNorm normalized name: norgestimate and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical and systemic medication
Trial: 8154950
Drug: Antibiotic consultant
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic consultant
Trial: 3337344
Drug: Bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5% (pH, 5.5) 3 mg/kg
Trial: 3337344
Drug: Alkalinized bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkalinized bupivacaine 0.5% (pH, 7.05-7.15) 3 mg/kg
Trial: 1347293
Drug: Intensive pharmacotherapy
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive pharmacotherapy
Trial: 21725168
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment - 1 Hz.
Trial: 19408036
Drug: Andrographis paniculata
RxNorm normalized name: Andrographis paniculata
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Andrographis paniculata (Paractin) tablets, 30% total andrographolides, administered three times a day for 14 weeks
Trial: 19408036
Drug: Andrographis paniculata
RxNorm normalized name: Andrographis paniculata
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Andrographis paniculata (Paractin) tablets
Trial: 17525777
Drug: Lumbar facet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar facet joint nerve blocks using bupivacaine and steroids (Group III)
Trial: 17525777
Drug: Lumbar facet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar facet joint nerve blocks using bupivacaine, Sarapin, and steroids (Group IV)
Trial: 17525777
Drug: Non-steroid group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroid group (Groups I and II)
Trial: 17525777
Drug: Steroid group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid group (Groups III and IV)
Trial: 6242150
Drug: HB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HB vaccine (5 micrograms, 3 injections at one-month intervals plus a booster after one year)
Trial: 6242150
Drug: HB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HB vaccine (5 micrograms, 2 doses given at intervals of 2 or 6 months plus a booster after one year)
Trial: 6242150
Drug: HB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HB vaccine
Trial: 6242150
Drug: HB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HB vaccine and DT-polio vaccine administered simultaneously
Trial: 16479196
Drug: Native Escherichia
RxNorm normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Native Escherichia coli L‐asparaginase (Crasnitin; n = 10)
Trial: 16479196
Drug: L‐asparaginase derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐asparaginase derived from Erwinia chrysanthemi (Erwinase; n = 10)
Trial: 3954392
Drug: Treatment discontinuation
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment discontinuation due to adverse reactions
Trial: 23163735
Drug: Conventional obesity
RxNorm normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional obesity therapy (COT)
Trial: 8403798
Drug: Bombesin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bombesin infusion
Trial: 3311923
Drug: Megestrol acetate/tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Megestrol acetate/tamoxifen (20 mg/day)
Trial: 24284856
Drug: Transdermal VALE-ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal VALE-ibuprofen (200 mg ibuprofen, 2.0 grams of drug product applied twice daily for 14 days)
Trial: 24284856
Drug: Transdermal VALE-ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal VALE-ibuprofen
Trial: 16126290
Drug: Nasal oxygen
RxNorm normalized name: TUBE,NASAL OXYGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal oxygen (4 L/min)
Trial: 14571151
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitor (paroxetine)
Trial: 14571151
Drug: Serotonin-noradrenaline reuptake
RxNorm normalized name: serotonin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonin-noradrenaline reuptake inhibitor (venlafaxine)
Trial: 14571151
Drug: Not applicable
RxNorm normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not applicable (absence of previous therapies, moderate baseline severity of obsessive-compulsive symptoms, low Hamilton Depressive Rating Scale scores)
Trial: 1982059
Drug: Oxprenolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxprenolol (80 mg/day)
Trial: 233458
Drug: Intrapleural administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapleural administration of Corynebacterium parvum (7 mg)
Trial: 30309816
Drug: Rufinamide (≤45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rufinamide (≤45 mg/kg/day)
Trial: 26660938
Drug: Visomitin eye
RxNorm normalized name: sisomicin
DrugBank: Sisomicin (DB12604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visomitin eye drops, self-administered three times daily (TID) for 6 weeks
Trial: 26660938
Drug: Placebo, self-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, self-administered three times daily (TID) for 6 weeks
Trial: 23260618
Drug: Mindfulness meditation
RxNorm normalized name: benzalkonium chloride Topical Foam [Meditize]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness meditation (30 min daily for 7 days)
Trial: 21189270
Drug: Oral amoxicillin
RxNorm normalized name: amoxicillin Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin (45mg/kg/day for 3 days)
Trial: 10845809
Drug: Day 1
RxNorm normalized name: New Day 1.5mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1 + 8 schedule (5FU and CTX 500mg/m2 day 1, epirubicin 40 mg/m2 day 1 and 8)
Trial: 10845809
Drug: Day 1
RxNorm normalized name: New Day 1.5mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1 schedule (5FU, CTX 500 mg/m2 and epirubicin 80 mg/m2 day 1)
Trial: 8271802
Drug: Outpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient treatment focused on drinking reduction techniques
Trial: 2961316
Drug: Regular chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regular chloroquine (10 mg base kg‐1)
Trial: 2961316
Drug: Enteric-coated chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteric-coated chloroquine (10 mg base kg‐1)
Trial: 2961316
Drug: Amodiaquine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amodiaquine (10 mg base kg‐1)
Trial: 2961316
Drug: Enteric-coated ferrous
RxNorm normalized name: ferrous sulfate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteric-coated ferrous sulphate (300 mg tablet)
Trial: 26686313
Drug: Anastrozole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole (1 mg oral daily for 5 years)
Trial: 26686313
Drug: Tamoxifen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20 mg oral daily for 5 years)
Trial: 4047104
Drug: Combined estrogen‐progestogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined estrogen‐progestogen (high-dose: 4 mg of estradiol)
Trial: 4047104
Drug: Combined estrogen‐progestogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined estrogen‐progestogen (other doses)
Trial: 20540639
Drug: Keto acids‐supplemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Keto acids‐supplemented low‐protein diet (sLP: 0.6‐0.8 g/kg IBW/d + 0.12 g/kg IBW/d of keto acids, n = 12)
Trial: 20540639
Drug: Low protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein diet (LP: 0.6‐0.8 g/kg IBW/d, n = 13)
Trial: 20540639
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein diet (HP: 1.0‐1.2 g/kg IBW/d, n = 14)
Trial: 16673835
Drug: Supportive-expressive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive-expressive group therapy plus education intervention
Trial: 8678510
Drug: Bolus i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus i.v. infusion of 5‐FU
Trial: 8678510
Drug: Protracted i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protracted i.v. infusion of 5‐FU
Trial: 8678510
Drug: Tomudex (pure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomudex (pure TS inhibitor)
Trial: 8678510
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of low‐dose cisplatin and 5‐FU
Trial: 8678510
Drug: New dihydropyrimidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New dihydropyrimidine dehydrogenase inhibitors
Trial: 8678510
Drug: New TS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New TS inhibitors
Trial: 1905621
Drug: ponalrestat 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ponalrestat 600 mg once daily for 6 weeks
Trial: 29986562
Drug: Standard antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antibiotics (B group)
Trial: 29986562
Drug: Prolonged antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged antibiotics (C group)
Trial: 29986562
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics (A group)
Trial: 29986562
Drug: Standard antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antibiotics (E group)
Trial: 29986562
Drug: Prolonged antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged antibiotics (F group)
Trial: 29986562
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics (D group)
Trial: 27470088
Drug: Bromelain (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromelain (500 mg/day)
Trial: 22211833
Drug: 2 units
RxNorm normalized name: Afrezza, 12 units inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 units FFP plus 2 g fibrinogen concentrate
Trial: 16091379
Drug: Irbesartan (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (1 mg/kg body weight) daily for 12 weeks
Trial: 12044433
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of protamine every 100 IU of heparin (Group A)
Trial: 12044433
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of protamine every 100 IU of heparin (Group B)
Trial: 10460567
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml bupivacaine 0.125% with epinephrine 1/800 000 (group B)
Trial: 10460567
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml saline (group S)
Trial: 7637642
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate 100 mg intramuscularly each month for 6 months
Trial: 7637642
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate treatment
Trial: 2576665
Drug: Verapamil 120
RxNorm normalized name: verapamil 120 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 120 mg three times a day for 4 weeks
Trial: 2576665
Drug: Nebivolol 5
RxNorm normalized name: nebivolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 5 mg once a day for 4 weeks
Trial: 31852672
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day prednisone (maintenance)
Trial: 31852672
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of 5 mg/day prednisone
Trial: 29955151
Drug: SSRI sertraline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRI sertraline
Trial: 25134887
Drug: English only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: English only (EO) treatment
Trial: 25134887
Drug: Bilingual skills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilingual skills in Spanish and English (BI) treatment
Trial: 25134887
Drug: Nonlinguistic cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonlinguistic cognitive processing (NCP) treatment
Trial: 22290266
Drug: D2 receptor
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D2 receptor occupancy >77%
Trial: 22290266
Drug: D2 receptor
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D2 receptor occupancy >80%
Trial: 8633944
Drug: Prophylactic high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic high-dose aprotinin (group 1)
Trial: 8633944
Drug: Postoperative low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Postoperative low-dose aprotinin (group 2)
Trial: 1444728
Drug: Amantadine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine (300 mg/d)
Trial: 6534186
Drug: Routine, eclectic,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine, eclectic, 28-d inpatient alcoholism treatment program
Trial: 31607468
Drug: WHO's recommended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WHO's recommended regimen (daily UNIMMAP containing 60 mg iron)
Trial: 31607468
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg screen-and-treat approach (daily UNIMMAP containing 60 mg iron for 7 days if weekly hepcidin was <2.5 μg/L)
Trial: 31607468
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg screen-and-treat approach (daily UNIMMAP containing 30 mg iron for 7 days if weekly hepcidin was <2.5 μg/L)
Trial: 31607468
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg screen-and-treat approach
Trial: 31607468
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg screen-and-treat approach
Trial: 20642296
Drug: Probiotic group
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic group (Lactobacillus acidophilus DDS‐1, Bifidobacterium lactis UABLA‐12 with fructo‐oligosaccharide at a dosage of 5 billion colony‐forming units twice daily for 8 weeks)
Trial: 15986013
Drug: New immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New immunosuppressive agents
Trial: 15986013
Drug: Various combination
RxNorm normalized name: various combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various combination protocols
Trial: 7780071
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion at 2.5 microgram/kg/min for 40 minutes (hydrated group)
Trial: 7780071
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion at 2.5 microgram/kg/min for 40 minutes (nonhydrated group)
Trial: 31566320
Drug: Orchid drug-coated
RxNorm normalized name: Orchis mascula whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orchid drug-coated balloon (DCB)
Trial: 21915733
Drug: Cefotetan disodium
RxNorm normalized name: Cefotetan Disodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotetan disodium (all doses)
Trial: 18324419
Drug: 23-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23-valent pneumococcal vaccine (PV) in group 1 (nephrotic children on high-dose prednisone)
Trial: 18324419
Drug: 23-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23-valent pneumococcal vaccine (PV) in group 2 (patients in remission)
Trial: 10545309
Drug: beta-blocker therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-blocker therapy (atenolol or metoprolol)
Trial: 8669218
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg methylnaltrexone IV at the end of surgery
Trial: 22333107
Drug: Hyperbaric air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric air therapy (Control)
Trial: 19617208
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G‐CSF) at a dosage of 1 microg/kg/day starting on the sixth day after ovulation.
Trial: 15128683
Drug: Potentially inappropriate
RxNorm normalized name: Potentilla discolor whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potentially inappropriate medications (PIMs) prescribed to seniors
Trial: 15128683
Drug: Oxybutynin prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin prescriptions
Trial: 8067217
Drug: Ropivacaine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine with adrenaline (5 ug.ml‐1)
Trial: 8067217
Drug: Bupivacaine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine with adrenaline (5 ug.ml‐1)
Trial: 8067217
Drug: Ropivacaine (plain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (plain solutions)
Trial: 8067217
Drug: Bupivacaine (plain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (plain solutions)
Trial: 31301451
Drug: Fecal Microbiota
RxNorm normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal Microbiota Transplantation (FMT) capsules (induction dose of 30 capsules at week 4 and maintenance dose of 12 capsules at week 8)
Trial: 25616438
Drug: n-3 FA
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 FA supplementation (1.7 g DHA and 0.6 g EPA daily for 6 months)
Trial: 24169736
Drug: Dance-based exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dance-based exercise therapy (1 hour)
Trial: 21958585
Drug: Mepolizumab (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab (750 mg, 2 single intravenous injections, 28 days apart)
Trial: 18986283
Drug: Appropriate antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appropriate antimicrobial treatment for mild CAP
Trial: 18986283
Drug: Ineffective therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ineffective therapies or no therapy
Trial: 11449032
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day of methylphenidate (MPH)
Trial: 9554249
Drug: Group 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: Combination of 50 micrograms ethinyl estradiol and 1 mg norethindrone per tablet on days 6-10, and 0.70 mg norethindrone only on days 11-19. Placebo on days 1-5 and 20-28.
Trial: 9554249
Drug: Group 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2: Combination of 50 micrograms ethinyl estradiol and 1 mg norethindrone per tablet on days 8-12, and 0.70 mg norethindrone only on days 13-21. Placebo on days 1-7 and 22-28.
Trial: 2977393
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg amlodipine
Trial: 2977393
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg amlodipine
Trial: 29273269
Drug: Extended-pulsed fidaxomicin
RxNorm normalized name: Fidaxomicin
DrugBank: Fidaxomicin (DB08874)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Extended-pulsed fidaxomicin (200 mg oral tablets, twice daily on days 1-5, then once daily on alternate days on days 7-25)
Trial: 29273269
Drug: Vancomycin (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (125 mg oral capsules, four times daily on days 1-10)
Trial: 26649741
Drug: Ceftazidime 2000
RxNorm normalized name: ceftazidime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 2000 mg and Avibactam 500 mg